Japan
The study will accumulate objective lifestyle data from around 2,000 participants.
They aim to bring down the period and costs for new drug development.
The clearance represents what could be the world's first regulatory approval of a DTx app for hypertension treatment.
The AI tech can spot signs of pancreatic cancer from non-contrast CT images.
It plans to develop an in-house cloud platform.
The company aims to help the self-testing market grow by licensing its core technology for transforming smartphones into IVD devices.
Its web-based platform also guides patients to access appropriate medical care.
A clinical trial has shown that it can predict AD progression with 88% and 84% accuracy in American and Japanese patients, respectively.
Also, Terumo has partnered with Glooko to enable diabetes data transfer from insulin patch pump to a data platform.
As part of the agreement, SoftBank will research market opportunities for the digital therapeutic, and it can negotiate an exclusive commercialization deal in Japan.